Obstetric antiphospholipid syndrome

Autoimmun Rev. 2012 Feb;11(4):288-95. doi: 10.1016/j.autrev.2011.10.006. Epub 2011 Oct 7.


Antiphospholipid syndrome (APS) in pregnancy has a serious impact on maternal and fetal morbidity. It causes recurrent pregnancy miscarriage and it is associated with other adverse obstetric findings like preterm delivery, intrauterine growth restriction, preeclampsia, HELLP syndrome and others. The 2006 revised criteria, which is still valid, is used for APS classification. Epidemiology of obstetric APS varies from one population group to another largely due to different inclusion criteria and lack of standardization of antibody detection methods. Treatment is still controversial. This topic should include a multidisciplinary team and should be individualized. Success here is based on strict control and monitoring throughout pregnancy and even in the preconception and postpartum periods. Further research in this field and unification of criteria are required to yield better therapeutic strategies in the future.

Publication types

  • Review

MeSH terms

  • Abortion, Habitual / epidemiology
  • Animals
  • Antibodies, Antiphospholipid / immunology*
  • Antibody-Dependent Cell Cytotoxicity
  • Antiphospholipid Syndrome* / diagnosis
  • Antiphospholipid Syndrome* / drug therapy
  • Antiphospholipid Syndrome* / epidemiology
  • Antiphospholipid Syndrome* / immunology
  • Aspirin / therapeutic use
  • Blood Coagulation / drug effects
  • Disease Models, Animal
  • Female
  • Heparin / therapeutic use
  • Humans
  • Immunotherapy / trends
  • Mice
  • Precision Medicine
  • Pregnancy
  • Pregnancy Complications* / drug therapy
  • Pregnancy Complications* / economics
  • Pregnancy Complications* / epidemiology
  • Pregnancy Complications* / immunology


  • Antibodies, Antiphospholipid
  • Heparin
  • Aspirin